Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework
出版年份 2017 全文链接
标题
Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework
作者
关键词
-
出版物
Journal of Biopharmaceutical Statistics
Volume 28, Issue 4, Pages 589-611
出版商
Informa UK Limited
发表日期
2017-09-09
DOI
10.1080/10543406.2017.1372775
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
- (2014) Joyce O'Shaughnessy et al. JOURNAL OF CLINICAL ONCOLOGY
- Sample size determination in group-sequential clinical trials with two co-primary endpoints
- (2014) Koko Asakura et al. STATISTICS IN MEDICINE
- A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints
- (2013) T. Sugimoto et al. BIOSTATISTICS
- Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis
- (2013) Xavier Paoletti et al. JNCI-Journal of the National Cancer Institute
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- Overall Survival: Patient Outcome, Therapeutic Objective, Clinical Trial End Point, or Public Health Measure?
- (2012) Everardo D. Saad et al. JOURNAL OF CLINICAL ONCOLOGY
- Progression-Free Survival: Meaningful or Simply Measurable?
- (2012) Christopher M. Booth et al. JOURNAL OF CLINICAL ONCOLOGY
- Sample size determination for clinical trials with co-primary outcomes: exponential event times
- (2012) Toshimitsu Hamasaki et al. PHARMACEUTICAL STATISTICS
- AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
- (2011) O. L. Chinot et al. ADVANCES IN THERAPY
- Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
- (2011) H. Hayashi et al. ANNALS OF ONCOLOGY
- Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies
- (2011) Marc Buyse et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
- (2011) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials
- (2010) Everardo D. Saad et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
- (2010) Marc Peeters et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)
- (2009) N. Katsumata et al. ANNALS OF ONCOLOGY
- Issues in Using Progression-Free Survival When Evaluating Oncology Products
- (2009) Thomas R. Fleming et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
- (2009) Kristine R. Broglio et al. JNCI-Journal of the National Cancer Institute
- The estimation of average hazard ratios by weighted Cox regression
- (2009) Michael Schemper et al. STATISTICS IN MEDICINE
- A statistical model for the dependence between progression-free survival and overall survival
- (2009) Frank Fleischer et al. STATISTICS IN MEDICINE
- The relationship between progression-free and post-progression survival in treating four types of metastatic cancer
- (2008) Russell J. Bowater et al. CANCER LETTERS
- Interim futility analysis with intermediate endpoints
- (2008) Bryan Goldman et al. Clinical Trials
- Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters?
- (2008) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer
- (2008) Tomasz Burzykowski et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More